Inactive Instrument

Analyst Reco. Coronado Biosciences Inc Nasdaq

Equities

Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	Mar. 19	MT
Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	Nov. 29	MT
B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating	23-08-22	MT
Cantor Fitzgerald Lowers Price Target on Fortress Biotech to $5 From $6, Maintains Overweight Rating	23-05-16	MT
Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target	22-08-04	MT
B. Riley Securities Lowers Fortress Biotech's Price Target to $6 from $8, Keeps Buy Rating	22-07-14	MT
Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating	22-03-29	MT
FORTRESS BIOTECH : B. Riley Lowers Fortress Biotech's PT to $8 from $9, Says Incremental Pipeline Updates Suggest Heightened Focus on Next-Gen Therapies; Keeps Buy Rating	21-06-17	MT
FORTRESS BIOTECH : Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating	21-04-20	MT
FORTRESS BIOTECH : B. Riley Raises Fortress Biotech's Price Target to $9 from $8 After 'Strong' Q4 2020 Results, Keeps Buy Rating	21-04-05	MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage	18-08-02	RE

No results for this search